Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma

Muneyuki Masuda, Hong Ying Ruan, Aya Ito, Torahiko Nakashima, Satoshi Toh, Takahiro Wakasaki, Ryuji Yasumatsu, Yuichiro Kutratomi, Shizuo Komune, I. Bernard Weinstein

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Overexpression of vascular endothelial growth factor (VEGF) is associated with angiogenic phenotypes and poor prognosis of numerous tumors, including head and neck squamous cell carcinoma (HNSCC). However, the precise mechanism that causes VEGF overexpression in HNSCC remains unknown. Since there is evidence that a transcriptional factor, signal transducers and activators of transcription 3 (Stat3), is constitutively activated in HNSCC and this activation is significantly associated with aggressive phenotypes of this disease, we investigated the roles of Stat3 activation on VEGF production and tumor angiogenesis in HNSCC both in vitro and in clinical samples. VEGF promoter assays with YCU-H891 cells demonstrated that dominant negative Stat3 significantly inhibited VEGF promoter activity in the full length (-2279 to +54) and two truncated forms of VEGF promoter luciferase-reporter construct (-1179 to 54) or (-1014 to +54), which retain the putative Stat3 responsive elements (-849 to -842). However, this was not seen in the shorter construct (-794 to +54), which lacks the putative Stat3 responsive elements. In the derivative of YCU-891 cells that stably express dominant negative Stat3 protein, cellular levels of VEGF mRNA and VEGF protein were significantly inhibited. In the 51 clinical samples obtained from the patients with tongue carcinoma, the expression levels of phosphorylated (activated) form of Stat3 protein were significantly correlated with VEGF (P < 0.05) production and intratumoral microvessel density IMVD (P < 0.01). These results strongly indicate that Stat3 directly up-regulates VEGF transcription and thereby promotes angiogenesis in HNSCC. Inhibition of Stat3 activity may provide a new anti-angiogenic therapy in HNSCC.

Original languageEnglish
Pages (from-to)785-790
Number of pages6
JournalOral Oncology
Volume43
Issue number8
DOIs
Publication statusPublished - Sep 1 2007

Fingerprint

STAT3 Transcription Factor
Vascular Endothelial Growth Factor A
Up-Regulation
Neoplasms
STAT Transcription Factors
Carcinoma, squamous cell of head and neck
Phenotype
Microvessels
Luciferases
Tongue
Transcriptional Activation
Carcinoma

All Science Journal Classification (ASJC) codes

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. / Masuda, Muneyuki; Ruan, Hong Ying; Ito, Aya; Nakashima, Torahiko; Toh, Satoshi; Wakasaki, Takahiro; Yasumatsu, Ryuji; Kutratomi, Yuichiro; Komune, Shizuo; Weinstein, I. Bernard.

In: Oral Oncology, Vol. 43, No. 8, 01.09.2007, p. 785-790.

Research output: Contribution to journalArticle

Masuda, Muneyuki ; Ruan, Hong Ying ; Ito, Aya ; Nakashima, Torahiko ; Toh, Satoshi ; Wakasaki, Takahiro ; Yasumatsu, Ryuji ; Kutratomi, Yuichiro ; Komune, Shizuo ; Weinstein, I. Bernard. / Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. In: Oral Oncology. 2007 ; Vol. 43, No. 8. pp. 785-790.
@article{5cdbf7395428447195a0dff8b41e16c1,
title = "Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma",
abstract = "Overexpression of vascular endothelial growth factor (VEGF) is associated with angiogenic phenotypes and poor prognosis of numerous tumors, including head and neck squamous cell carcinoma (HNSCC). However, the precise mechanism that causes VEGF overexpression in HNSCC remains unknown. Since there is evidence that a transcriptional factor, signal transducers and activators of transcription 3 (Stat3), is constitutively activated in HNSCC and this activation is significantly associated with aggressive phenotypes of this disease, we investigated the roles of Stat3 activation on VEGF production and tumor angiogenesis in HNSCC both in vitro and in clinical samples. VEGF promoter assays with YCU-H891 cells demonstrated that dominant negative Stat3 significantly inhibited VEGF promoter activity in the full length (-2279 to +54) and two truncated forms of VEGF promoter luciferase-reporter construct (-1179 to 54) or (-1014 to +54), which retain the putative Stat3 responsive elements (-849 to -842). However, this was not seen in the shorter construct (-794 to +54), which lacks the putative Stat3 responsive elements. In the derivative of YCU-891 cells that stably express dominant negative Stat3 protein, cellular levels of VEGF mRNA and VEGF protein were significantly inhibited. In the 51 clinical samples obtained from the patients with tongue carcinoma, the expression levels of phosphorylated (activated) form of Stat3 protein were significantly correlated with VEGF (P < 0.05) production and intratumoral microvessel density IMVD (P < 0.01). These results strongly indicate that Stat3 directly up-regulates VEGF transcription and thereby promotes angiogenesis in HNSCC. Inhibition of Stat3 activity may provide a new anti-angiogenic therapy in HNSCC.",
author = "Muneyuki Masuda and Ruan, {Hong Ying} and Aya Ito and Torahiko Nakashima and Satoshi Toh and Takahiro Wakasaki and Ryuji Yasumatsu and Yuichiro Kutratomi and Shizuo Komune and Weinstein, {I. Bernard}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.oraloncology.2006.10.007",
language = "English",
volume = "43",
pages = "785--790",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma

AU - Masuda, Muneyuki

AU - Ruan, Hong Ying

AU - Ito, Aya

AU - Nakashima, Torahiko

AU - Toh, Satoshi

AU - Wakasaki, Takahiro

AU - Yasumatsu, Ryuji

AU - Kutratomi, Yuichiro

AU - Komune, Shizuo

AU - Weinstein, I. Bernard

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Overexpression of vascular endothelial growth factor (VEGF) is associated with angiogenic phenotypes and poor prognosis of numerous tumors, including head and neck squamous cell carcinoma (HNSCC). However, the precise mechanism that causes VEGF overexpression in HNSCC remains unknown. Since there is evidence that a transcriptional factor, signal transducers and activators of transcription 3 (Stat3), is constitutively activated in HNSCC and this activation is significantly associated with aggressive phenotypes of this disease, we investigated the roles of Stat3 activation on VEGF production and tumor angiogenesis in HNSCC both in vitro and in clinical samples. VEGF promoter assays with YCU-H891 cells demonstrated that dominant negative Stat3 significantly inhibited VEGF promoter activity in the full length (-2279 to +54) and two truncated forms of VEGF promoter luciferase-reporter construct (-1179 to 54) or (-1014 to +54), which retain the putative Stat3 responsive elements (-849 to -842). However, this was not seen in the shorter construct (-794 to +54), which lacks the putative Stat3 responsive elements. In the derivative of YCU-891 cells that stably express dominant negative Stat3 protein, cellular levels of VEGF mRNA and VEGF protein were significantly inhibited. In the 51 clinical samples obtained from the patients with tongue carcinoma, the expression levels of phosphorylated (activated) form of Stat3 protein were significantly correlated with VEGF (P < 0.05) production and intratumoral microvessel density IMVD (P < 0.01). These results strongly indicate that Stat3 directly up-regulates VEGF transcription and thereby promotes angiogenesis in HNSCC. Inhibition of Stat3 activity may provide a new anti-angiogenic therapy in HNSCC.

AB - Overexpression of vascular endothelial growth factor (VEGF) is associated with angiogenic phenotypes and poor prognosis of numerous tumors, including head and neck squamous cell carcinoma (HNSCC). However, the precise mechanism that causes VEGF overexpression in HNSCC remains unknown. Since there is evidence that a transcriptional factor, signal transducers and activators of transcription 3 (Stat3), is constitutively activated in HNSCC and this activation is significantly associated with aggressive phenotypes of this disease, we investigated the roles of Stat3 activation on VEGF production and tumor angiogenesis in HNSCC both in vitro and in clinical samples. VEGF promoter assays with YCU-H891 cells demonstrated that dominant negative Stat3 significantly inhibited VEGF promoter activity in the full length (-2279 to +54) and two truncated forms of VEGF promoter luciferase-reporter construct (-1179 to 54) or (-1014 to +54), which retain the putative Stat3 responsive elements (-849 to -842). However, this was not seen in the shorter construct (-794 to +54), which lacks the putative Stat3 responsive elements. In the derivative of YCU-891 cells that stably express dominant negative Stat3 protein, cellular levels of VEGF mRNA and VEGF protein were significantly inhibited. In the 51 clinical samples obtained from the patients with tongue carcinoma, the expression levels of phosphorylated (activated) form of Stat3 protein were significantly correlated with VEGF (P < 0.05) production and intratumoral microvessel density IMVD (P < 0.01). These results strongly indicate that Stat3 directly up-regulates VEGF transcription and thereby promotes angiogenesis in HNSCC. Inhibition of Stat3 activity may provide a new anti-angiogenic therapy in HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=34547975508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547975508&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2006.10.007

DO - 10.1016/j.oraloncology.2006.10.007

M3 - Article

C2 - 17169602

AN - SCOPUS:34547975508

VL - 43

SP - 785

EP - 790

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 8

ER -